OncoMatch/Clinical Trials/NCT07149363
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Is NCT07149363 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Durvalumab 50 MG/ML for small cell lung cancer (sclc).
Treatment: Durvalumab 50 MG/ML — This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Small Cell Lung Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-L1 therapy (durvalumab)
Prior treatment with durvalumab
Cannot have received: radiation therapy
Exception: post-operative radiation for resected small cell lung cancer is acceptable in N1 disease; no other prior radiation for small cell lung cancer
No other prior radiation for small cell lung cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Virginia Comprehensive Cancer Center · Charlottesville, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07149363 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages